2nd July 2022 | Pharma Updates

Pharma can no longer rely on traditional sales and marketing to introduce new drugs

The majority of pharmaceutical drug launches over the past three years “underperformed expectations, ” demonstrating the need for a significant shift in how we approach the sale and marketing of new medications.

Dr. Reddy's settles disagreement with Indivior Inc.

Dr. Reddy’s Laboratories announced that it had reached a settlement in its patent dispute with Indivior Inc, Indivior UK Ltd, and Aquestive Therapeutics Inc. for its generic version of the medicine Suboxone, which treats opiate addiction.

Alkem Labs receives approval from CDSCO panel to conduct an anti-epileptic drug BE study

The CDSCO Subject Expert Committee recommended that Alkem Laboratories be granted authorization to perform a BE study of Perampanel suspension 0.5mg/ml according to the proposed protocol to treat epilepsy.

Sierra Oncology acquired by GlaxoSmithKline

After receiving shareholder approval on June 29, GlaxoSmithKline has now fully acquired Sierra Oncology. Momelotinib, a late-stage asset to treat anemia in myelofibrosis patients, is made available to GSK as a result of the acquisition.

Sirana collaborates with Pfizer to find possible therapy options for bone ailments

The pharma giant Pfizer and Sirana Pharma have announced a research collaboration. The agreement, as per the company, will assist them in looking into the possibility of discovering a brand-new therapeutic idea for serious and uncommon bone illnesses.

Oxford Biomedica signs new agreement to manufacture AstraZeneca COVID shots

The COVID-19 vaccine from AstraZeneca may be produced by Oxford Biomedica in Britain for a further three years, but no volumes were specified, indicating diminishing demand for the shot.

Omicron BA.4 and BA.5 variant-targeting Covid booster approved by USFDA

US Food and Drug Administration (FDA) has advised vaccine producers to provide follow-up doses that target the Omicron BA.4 and BA.5 forms of Covid-19. The Omicron BA.4 and BA.5 variants are known to resist vaccine-induced immunity.